申请人:Isis Pharmceuticals, Inc.
公开号:US05646265A1
公开(公告)日:1997-07-08
2'-O-alkylated guanosine, uridine, cytidine, and 2,6-diaminopurine 3'-O-phosphoramidites are prepared by alkylating nucleoside precursors, adding suitable blocking groups and phosphitylating. Alkylation is effected on 2,6-diamino-9-(.beta.-D-ribofuranosyl)purine followed by deamination to prepare guanosine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected on a dialkyl stannylene derivative of uridine to prepare uridine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on cytidine to prepare cytidine 2'-O-alkylated 3'-O-phosphormidites. Alkylation is effected directly on 2,6-diaminopurine to prepare 2,6-diaminopurine 2'-O-alkylated 3'-O-phosphormidites.
2'-O-烷基化
鸟苷、
尿苷、
胞苷和
2,6-二氨基嘌呤3'-O-
磷酰胺酯是通过烷基化核苷前体、添加适当的阻断基团和
磷酰化来制备的。烷基化是在2,6-二
氨基-9-(β-
D-核糖呋喃基)
嘌呤上进行的,随后进行去
氨基化以制备
鸟苷2'-O-烷基化3'-O-
磷酰胺酯。烷基化是在
尿苷的二烷基基
锡衍
生物上进行的,以制备
尿苷2'-O-烷基化3'-O-
磷酰胺酯。烷基化是直接在
胞苷上进行的,以制备
胞苷2'-O-烷基化3'-O-
磷酰胺酯。烷基化是直接在
2,6-二氨基嘌呤上进行的,以制备
2,6-二氨基嘌呤2'-O-烷基化3'-O-
磷酰胺酯。